我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

心力衰竭时高迁移率族蛋白（HMG）B1和可溶性晚期糖基化终产物受体（sRAGE）的变化(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第3期
页码:
356-360
栏目:
综述
出版日期:
2017-01-25

文章信息/Info

Title:
Changes of high mobility protein B1 and soluble advanced glycation end product receptor in heart failure
作者:
敖文杰; 邹卓璇 综述; 张瑞英 审校
哈尔滨医科大学附属第一医院心内三科，黑龙江 哈尔滨 150001
Author(s):
AO Wen-jie;  ZOU Zhuo-xuan;  ZHANG Rui-ying
Third Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China
关键词:
高迁移率族蛋白B1; 可溶性晚期糖基化终产物受体; 心力衰竭
Keywords:
High mobility group protein B1;  soluble advanced glycation end product receptor;  heart failure
分类号:
R541
DOI:
-
文献标识码:
A
摘要:
心力衰竭（HF）是多种心脏疾病的终末阶段，也是一种慢性炎症性疾病。高迁移率族蛋白(HMG)B1是机体非特异性炎症反应的敏感标志物，胞外的HMGB1通过与其高亲和力受体晚期糖基化终产物受体（RAGE）结合后参与心血管疾病的发生发展，而可溶性RAGE（sRAGE）可竞争性抑制全长RAGE的生物学效应，竞争结合HMGB1，从而减轻甚至抑制炎症反应，延缓HF的发生和发展，现就近年来研究发现的HMGB1、sRAGE在心血管疾病中所起的作用及其在治疗方面的进展做一综述。
Abstract:
Heart failure is considered to be a chronic inflammatory disease. High mobility group protein B1 (HMGB1) is a sensitive marker of the body’s nonspecific inflammation. Extracellular HMGB1 through its high affinity combined with receptor advanced glycation end product receptor (RAGE) participates in the occurrence of cardiovascular disease development. sRAGE can competitively inhibit RAGE biological effect and competitively combine with HMGB1 to reduce and inhibit inflammation, thus delaying the occurrence and development of heart failure. This article summarizes the recent progress in the role of HMGB1 and sRAGE in the development and treatment of cardiovascular disease.

参考文献/References

[1]Li J,Kokkola R,Tabibzadeh S,et al.Structural basis for the proinfiammatory cytokine activity of higll mobility group box 1[J].Mol Med,2003,9(1-2):37-45.
[2]Naglova H,Bucova M.HMGB1 and its physiological and pathological roles[J].Bratisl Lek Listy,2012,113(3):163-171.
[3]Kokkola R,Andersson A,Mullins G,et al.RAGE is the major receptor for the proinflammatory activity of HMGBI in rodent macrophages[J].Scand J Ilmmunol,2005,61(1):1-9.
[4]Degryse B,Bonaldi T,Scaffidi P,et al.The high mobility group(HMG)boxes of the nuclear protein HMGI induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells[J].J Cell Biol,2001,152(6):1197-1206.
[5]Sun M,Dawood F,Wen WH,et al.Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction[J].Circulation,2004,110(20):3221-3228.
[6]Nian M,Lee P,Khaper N,et al.Inflammatory cytokines and postmyocardial infarction remodeling[J].Circ Res,2004,94(12):1543-1553.
[7]Maekawa Y,Anzai T,Yoshikawa T,et al.Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling[J].J Am Coll Cardiol,2002,39(2):241-246.
[8]Volz HC,Laohachewin D,Schellberg D,et al.HMGBl is an independent predictor of death and heart transplantation in heart failure[J].Clin Res Cardiol,2012,101(6):427-435.
[9]Wang LJ,Lu L,Zhang FR,et al.Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure[J].Eur J Heart Fail,2011,13(4):440-449.
[10]Funayama A,Shishido T,Netsu S,et al.Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure[J].Cardiovasc Res,2013,99(4):657-664.
[11]Germani A,Limana F,Capogrossi MC.Pivotal advances:high-mobility group box 1 protein--a cytokine with a role in cardiac repair[J].Leukoc Biol,2007,81(1):41-45.
[12]Limana F,Esposito G,D’Arcangelo D,et al.HMGBl attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206 Mediated inhibition of TIMP-3[J].PLoS One,2011,6(6):e19845.
[13]Abraham E,Arcaroli J,Carmody A,et al.HMG-1 as a mediator of acute lung inflammation[J].J Immunol,2000,165(6):2950-2954.
[14]Yang H,Ochani M,Li J,et al.Reversing established sepsis with antagonists of endogenous high-mobility group box 1[J].ProcNatl Acad Sci U S A,2004,101(1):296-301.
[15]Andrassy M,Volz HC,Igwe JC,et al.High-mobility group box-1 in ischemia-reperfusion injury of the heart[J].Circulation,2008,117(25):3216-3226.
[16]Zhang L,Bukulin M,Kojro E,et al.Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases[J].J Biol Chem,2008,283(51):35507-35516.
[17]Jang Y,Kim JY,Kang SM,et al.Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans[J].Metabolism,2007,56(2):199-205.
[18]Hofmann MA,Drury S,Hudson BI,et al.RAGE and arthritis:the G82S polymorphism amplifies the inflammatory response[J].Genes Immun,2002,3(3):123-135.
[19]Falcone C,Geroldi D,Buzzi MP,et al.The -374T/A RAGE polymorphism protects against future cadiac event in nondiabetic patients with coronary artery disease[J].Arch Med Res,2008,39(3):320-325.
[20]Basta G.Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications[J].Atherosclerosis,2008,196:9-21.
[21]Falcone C,Emanuele E,D’Angelo A,et al.Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men[J].Arterioscler Thromb Vasc Biol,2005,25(5):1032-1037.
[22]Nakamura K,Yamagishi S,Adachi H, et al.Elevation of soluble form of receptor for advanced glycation end products(sRAGE)in diabetic subjects with coronary artery disease[J].Diabetes Metab Res Rev,2007,23(5):368-371.
[23]Harja E,Bu DX,Hudson BI,et al.Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice［J］. J Clin Invest,2008,118(1):183-194.
[24]Burke AP,Kolodgie FD,Zieske A,et al.Morphologic findings of coronary atherosclerotic plaques in diabetics:a postmortem study[J].Arterioscler Thromb Vasc Biol,2004,24(7):1266-1271.
[25]Koyama Y,Takeishi Y,Niizeki T,et al.Soluble Receptor for advanced glycation end products(RAGE)is a prognostic factor for heart failure[J].J Card Fail,2008,14(2):133-139.
[26]Raposeiras-Roubín S,Rodifio-Janeiro BK,Grigorian-Shamagian L,et al.Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients,independent of advanced glycation end products levels:New Roles for Soluble RAGE[J].Eur J Heart Fail,2010,12(10):1092-1100.
[27]Petrova R,Yamamoto Y,Muraki K,et al.Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes[J].J Mol Cell Cardiol,2002,34(10):1425-1431.
[28]Quade-Lyssy P,Kanarek AM,Baiersd?rfer M,et al.Statins stimulate the production of a soluble form of the receptor for advanced glycation end products[J].J Lipid Res,2013,54(11):3052-3061.

备注/Memo

备注/Memo:
收稿日期：2015-10-21.基金项目：黑龙江省教育厅科学技术研究项目资助(12541291) 通讯作者：张瑞英，主任医师，主要从事心力衰竭研究 Email：zhangruiyingha@126.com 作者简介：敖文杰，硕士生 Email：754741218@qq.com
更新日期/Last Update: 2017-02-20